{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:13Z","timestamp":1790957533209,"version":"4.1.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>Arrhythmic events such as atrial fibrillation (AF) are tightly associated with an increased risk of heart failure (HF). Previous studies have shown inconsistent results regarding the association between sodium-glucose co-transporter 2 inhibitors (SGLT2i) and the risk of arrhythmia. The purpose of this study was to investigate the association of SGLT2i treatment with arrhythmia outcomes in clinical trials of patients with HF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched Embase, PubMed, Web of Science, Medline, The Cochrane Library, and JAMA databases to identify appropriate randomized controlled trials (RCTs) of SGLT2i interventions. Endpoint outcomes included AF, atrial flutter (AFL), AF\/AFL, ventricular fibrillation (VF), ventricular tachycardia (VT), VF\/VT, and bradycardia. A random-effects model was used for the meta-analysis of all outcomes. The risk of bias and quality of evidence was assessed by using the Cochrane tool and assessment framework.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of 1,725 citations, 9 trials were included in this study, with follow-up from 4 weeks to 52 weeks for 10,344 participants (mean age 68.27 years; 69.62% of participants were men). Compared with placebo, SGLT2i reduced the incidence of AF by 37% [ratio risk (RR) 0.63; 95% confidence interval (CI) 0.45\u20130.87; <jats:italic>p<\/jats:italic> &amp;lt; 0.05] and AF\/AFL by 34% (RR 0.66; 95% CI 0.49\u20130.90; <jats:italic>p<\/jats:italic> &amp;lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>SGLT2i can reduce the risk of cardiac arrhythmias, particularly the AF. Our study provides strong evidence for recommending the use of SGLT2i in patients with HF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>PROSPERO, identifier: CRD42022296696.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.902923","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T05:46:48Z","timestamp":1652852808000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3389","volume":"9","author":[{"given":"Ziwei","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jchf.2019.03.005","article-title":"Heart failure and atrial fibrillation, like fire and fury","volume":"7","author":"Carlisle","year":"2019","journal-title":"JACC Heart Fail."},{"key":"B2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.115.018614","article-title":"Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved vs. reduced ejection fraction","volume":"133","author":"Santhanakrishnan","year":"2016","journal-title":"Circulation."},{"key":"B3","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/heartjnl-2020-318081","article-title":"Update on management of atrial fibrillation in heart failure: a focus on ablation","volume":"108","author":"Mulder","year":"2021","journal-title":"Heart."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1056\/NEJMc1600827","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2016","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1161\/CIR.0000000000000935","article-title":"Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American heart association","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation."},{"key":"B10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","article-title":"SGLT-2 inhibitors and atrial fibrillation in the food and drug administration adverse event reporting system","volume":"20","author":"Bonora","year":"2021","journal-title":"Cardiovasc Diabetol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","article-title":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Cardiovasc Diabetol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/dom.14211","article-title":"Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials","volume":"23","author":"Okunrintemi","year":"2021","journal-title":"Diabetes Obes Metab."},{"key":"B14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/ejhf.2381","article-title":"Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF","volume":"24","author":"Butt","year":"2021","journal-title":"Eur J Heart Fail."},{"key":"B15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/2047487318755531","article-title":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis","volume":"25","author":"Usman","year":"2018","journal-title":"Eur J Prev Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation."},{"key":"B17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur Heart J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail."},{"key":"B19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10557-018-06850-0","article-title":"Rationale and design of the EMPA-TROPISM trial (ATRU-4): are the \u201ccardiac benefits\u201d of empagliflozin independent of its hypoglycemic activity?","volume":"33","author":"Santos-Gallego","year":"2019","journal-title":"Cardiovasc Drugs Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-reduced trial","volume":"77","author":"Packer","year":"2021","journal-title":"J Am Coll Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.15420\/cfr.2020.23","article-title":"Sodium-glucose co-transporter 2 inhibitors in heart failure: recent data and implications for practice","volume":"6","author":"Rosano","year":"2020","journal-title":"Card Fail Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/ehf2.13406","article-title":"Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure","volume":"8","author":"Hundertmark","year":"2021","journal-title":"ESC Heart Fail."},{"key":"B24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.tcm.2016.07.008","article-title":"Impact of empagliflozin in patients with diabetes and heart failure","volume":"27","author":"Pham","year":"2017","journal-title":"Trends Cardiovasc Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev."},{"key":"B26","first-page":"575","article-title":"Left atrial ultrastructure in mitral valvular disease","volume":"89","author":"Thiedemann","year":"1977","journal-title":"Am J Pathol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.ddmec.2010.07.002","article-title":"Regulation of mitochondrial processes: a target for heart failure","volume":"7","author":"Palaniyandi","year":"2010","journal-title":"Drug Discov Today Dis Mech."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1161\/RES.0000000000000104","article-title":"Mitochondrial function, biology, and role in disease: a scientific statement from the American heart association","volume":"118","author":"Murphy","year":"2016","journal-title":"Circ Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"36027","DOI":"10.1074\/jbc.M304854200","article-title":"Production of reactive oxygen species by mitochondria: central role of complex III","volume":"278","author":"Chen","year":"2003","journal-title":"J Biol Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12933-019-0984-0","article-title":"Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?","volume":"19","author":"Yurista","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1253\/circj.CJ-13-1187","article-title":"Production of reactive oxygen species in the diabetic heart. Roles of mitochondria and NADPH oxidase","volume":"78","author":"Teshima","year":"2014","journal-title":"Circ J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"856386","DOI":"10.3389\/fphar.2022.856386","article-title":"An effective sodium-dependent glucose transporter 2 inhibition, canagliflozin, prevents development of hypertensive heart failure in dahl salt-sensitive rats","volume":"13","author":"He","year":"2022","journal-title":"Front Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","article-title":"Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes","volume":"16","author":"Habibi","year":"2017","journal-title":"Cardiovasc Diabetol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/JOE-17-0457","article-title":"Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury","volume":"236","author":"Tanajak","year":"2018","journal-title":"J Endocrinol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e017483","DOI":"10.1161\/JAHA.119.017483","article-title":"Canagliflozin suppresses atrial remodeling in a canine atrial fibrillation model","volume":"10","author":"Nishinarita","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care."},{"key":"B38","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","article-title":"The failing heart relies on ketone bodies as a fuel","volume":"133","author":"Aubert","year":"2016","journal-title":"Circulation."},{"key":"B39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10741-020-10041-1","article-title":"Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure","volume":"26","author":"Dutka","year":"2021","journal-title":"Heart Fail Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"H1060","DOI":"10.1152\/ajpheart.00646.2012","article-title":"Ketone body metabolism and cardiovascular disease","volume":"304","author":"Cotter","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fragi.2021.681513","article-title":"Beta-hydroxybutyrate, friend or foe for stressed hearts","author":"Chu","year":"2021","journal-title":"Front Aging"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e147371","DOI":"10.1172\/jci.insight.147371","article-title":"Attenuating persistent sodium current-induced atrial myopathy and fibrillation by preventing mitochondrial oxidative stress","volume":"6","author":"Avula","year":"2021","journal-title":"JCI Insight"},{"key":"B43","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00395-010-0136-x","article-title":"Diastolic dysfunction and arrhythmias caused by overexpression of CaMKII\u03b4(C) can be reversed by inhibition of late Na(+) current","volume":"106","author":"Sossalla","year":"2011","journal-title":"Basic Res Cardiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1016\/j.jacc.2009.12.055","article-title":"Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium","volume":"55","author":"Sossalla","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1016\/j.jacc.2010.01.046","article-title":"Enhanced late Na(+) currents in atrial fibrillation new drug target or just an epiphenomenon?","volume":"55","author":"Schotten","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"7976","DOI":"10.3390\/ijms22157976","article-title":"Cardioprotection by sglt2 inhibitors-does it all come down to Na(+)?","volume":"22","author":"Trum","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/cvr\/cvx149","article-title":"Cardiac effects of SGLT2 inhibitors: the sodium hypothesis","volume":"114","author":"Bertero","year":"2018","journal-title":"Cardiovasc Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia."},{"key":"B49","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia."},{"key":"B50","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1002\/ehf2.13024","article-title":"Empagliflozin inhibits Na(+) \/H(+) exchanger activity in human atrial cardiomyocytes","volume":"7","author":"Trum","year":"2020","journal-title":"ESC Heart Fail."},{"key":"B51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcb.10631","article-title":"Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1)","volume":"90","author":"Zhou","year":"2003","journal-title":"J Cell Biochem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","article-title":"Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart","volume":"467","author":"Vrhovac","year":"2015","journal-title":"Pflugers Arch."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e0130605","DOI":"10.1371\/journal.pone.0130605","article-title":"Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice","volume":"10","author":"Kashiwagi","year":"2015","journal-title":"PLoS ONE."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.2147\/DDDT.S114932","article-title":"Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date","volume":"11","author":"Cinti","year":"2017","journal-title":"Drug Des Devel Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e018298","DOI":"10.1161\/JAHA.120.018298","article-title":"do Carmo JM, Wang Z, da Silva AA, et al. Direct cardiac actions of the sodium glucose co-transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure-overload heart failure","volume":"10","author":"Li","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B57","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1093\/eurheartj\/ehab420","article-title":"Effects of canagliflozin on human myocardial redox signalling: clinical implications","volume":"42","author":"Kondo","year":"2021","journal-title":"Eur Heart J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"114674","DOI":"10.1016\/j.bcp.2021.114674","article-title":"Dapagliflozin attenuates arrhythmic vulnerabilities by regulating connexin43 expression via the AMPK pathway in post-infarcted rat hearts","volume":"192","author":"Lee","year":"2021","journal-title":"Biochem Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"119440","DOI":"10.1016\/j.lfs.2021.119440","article-title":"Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia","volume":"276","author":"Azam","year":"2021","journal-title":"Life Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"Eur Heart J."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s40265-021-01565-3","article-title":"Could sodium\/glucose co-transporter-2 inhibitors have antiarrhythmic potential in atrial fibrillation? Literature review and future considerations","volume":"81","author":"Vrachatis","year":"2021","journal-title":"Drugs."},{"key":"B63","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-020-01105-5","article-title":"SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials","volume":"19","author":"Li","year":"2020","journal-title":"Cardiovasc Diabetol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.902923\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T05:46:52Z","timestamp":1652852812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.902923\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":63,"alternative-id":["10.3389\/fcvm.2022.902923"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.902923","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"article-number":"902923"}}